This hypothesis will be tested using proteomic data from the SELECT trial 36 for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1
Serum IGF-1 levels, growth velocity and head circumference should be monitored during treatment and kept in the normal range
With the rising global prevalence of metabolic diseases like obesity and type 2 diabetes, the demand for glucagon-like peptide-1 (GLP-1) receptor agonist drugs continues to grow
The right next step depends on the reader's evidence, safety, cost, access, and provider-review needs
Anti-diabetic drugs repositioning for tumor treatment: the other face of the coin The previous chapter is suggestive of a collective practicable repositioning of most of the anti-diabetic drugs, in particular for the treatment of TC
In contrast to its effect on obesity, tirzepatide has shown remarkable results in neuroprotective qualities